Germany’s Cannabis Market Is Getting Bigger—and More Complicated

By Pacific Rim Fusion — European Cannabis Intelligence

Germany was supposed to be one of Europe’s great cannabis experiments.

After partially legalizing cannabis in 2024, the country quickly became one of the most closely watched markets on the planet.

But Germany’s cannabis story is no longer simply about legalization.

It’s about medical demand, imports, regulation and who gets to control the European supply chain.

And that’s where things are getting interesting.

Germany’s Medical Market Is Becoming the Prize

Germany’s adult-use reforms attracted much of the international attention.

But investors have increasingly focused on something else:

medical cannabis.

International companies are building positions in Germany because the country’s medical market has become a major gateway into Europe.

Organigram, for example, has expanded its German presence through its acquisition of Berlin-based Sanity Group and is using that position as part of a broader European strategy involving markets such as Switzerland, Poland and the UK.

That’s a very different strategy from simply selling cannabis flower.

It’s about building a European network.

Why Germany Matters So Much

Germany has scale.

It has a large population, a sophisticated healthcare system and a substantial pharmaceutical industry.

It also sits in the middle of Europe.

For cannabis companies, that makes Germany strategically valuable beyond its domestic consumer base.

The company that establishes itself in Germany isn’t necessarily thinking only about German patients.

It may be thinking about the next five or ten European markets.

But Regulation Is Moving Too

Germany’s medical cannabis system is also under political pressure.

Policymakers have been debating tighter rules around prescribing and dispensing, following concerns about the rapid growth of medical cannabis imports and prescriptions.

The debate is complicated because legitimate patients depend on access while regulators are attempting to prevent abuse and build a sustainable medical framework.

That creates a familiar cannabis dilemma:

How do you prevent misuse without making legitimate access unnecessarily difficult?

Germany is still figuring that out.

The Global Cannabis Industry Is Watching

Germany’s experiment matters because Europe doesn’t have a single cannabis market.

It has dozens of national regulatory systems sitting next to one another.

One country may allow medical flower.

Another may require pharmaceutical preparations.

Another may permit limited adult use.

Another may prohibit most forms of cannabis.

For international companies, navigating those differences can be more difficult than growing the plant itself.

That is why European cannabis is increasingly becoming a game of regulatory expertise.

The New Cannabis Arms Race

The first cannabis arms race was about cultivation.

Who could grow the most?

Who had the biggest greenhouse?

Who had the strongest genetics?

The next one is different.

Who has the best pharmaceutical standards?

Who can navigate European regulations?

Who has access to doctors and pharmacies?

Who can build a reliable international supply chain?

Who owns the patient relationship?

Those questions are increasingly defining the European market.

Germany Could Become Europe’s Cannabis Hub

The irony is that Germany doesn’t necessarily need to become Europe’s biggest recreational market to become Europe’s most important cannabis market.

It could instead become the continent’s medical and commercial hub.

Companies are already positioning themselves accordingly.

Aurora is expanding its UK medical infrastructure. Tilray is connecting European cultivation and manufacturing with UK patient access. Organigram is building a wider European footprint from Germany.

The pattern is hard to miss.

Europe’s cannabis future is becoming increasingly interconnected.

Germany is right in the middle of it.

Editor’s note: Cannabis laws and medical access requirements vary substantially across Europe and can change quickly. This article is general industry commentary and is not legal or medical advice.